ADAGENE INC-ADR (ADAG)

US0053291078 - ADR

1.47  -0.05 (-3.29%)

ADAGENE INC-ADR

NASDAQ:ADAG (9/28/2023, 7:00:00 PM)

1.47

-0.05 (-3.29%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-30 2023-08-30/amc
Earnings (Next)N/A N/A
Ins OwnersN/A
Inst Owners9.38%
Market Cap64.44M
Shares43.83M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts83.64
IPO02-09 2021-02-09
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADAG Daily chart

Company Profile

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 248 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Company Info

ADAGENE INC-ADR

4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park

Suzhou JIANGSU 215123

P: 8651287773632.0

CEO: Peter (Peizhi) Luo

Employees: 248

Website: https://www.adagene.com/

ADAG News

News Image22 days ago - Adagene Inc.Adagene to Present at Investor and Scientific Conferences in September
News Image22 days ago - Adagene Inc.Adagene to Present at Investor and Scientific Conferences in September

– Adagene’s CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies – ...

News Imagea month ago - Adagene Inc.Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
News Imagea month ago - Adagene Inc.Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated...

News Image5 months ago - Adagene Inc.Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
News Image5 months ago - Adagene Inc.Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology...

ADAG Twits

Here you can normally see the latest stock twits on ADAG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example